UBS analyst Michael Goldsmith maintains Boston Properties (NYSE:BXP) with a Neutral and lowers the price target from $131 to $98.
Mereo BioPharma Reiterates Previous Cash Runway Guidance; Current Cash Expected To Fund Operations Into 2026
Mereo BioPharma Group plc (NASDAQ:MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today provided an update on its pipeline programs as well